<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="243">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138786</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-010</org_study_id>
    <nct_id>NCT02138786</nct_id>
  </id_info>
  <brief_title>Selinexor in Initial or Relapsed/Refractory Richter's Transformation</brief_title>
  <acronym>SIRRT</acronym>
  <official_title>A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Initial or Refractory and/or Relapsed Richter's Transformation (RT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, Phase 2, single arm, open-label study of oral selinexor monotherapy
      in patients in patients with Richter's transformation, arising in the setting of prior CLL,
      after at least one chemo-immunotherapy regimen for CLL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, Phase 2, single arm, open-label study of oral selinexor monotherapy in
      patients with Richter's transformation, arising in the setting of prior CLL, documented by
      histologically confirmed lymphoma, including diffuse large B-cell (DLBCL) and immunoblastic
      variants. Eligible patients must have had at least one prior regimen for CLL. Approximately
      50 patients are anticipated to be treated in this study. Eligible patients following
      screening will receive selinexor orally twice weekly (e.g., Monday and Wednesday or Tuesday
      and Thursday) at a dose of 60 mg. The selinexor dose may be increased to 80 mg after Cycle 1
      unless clinically contraindicated. Patients may continue in multiple treatment cycles at a
      given dose; there is no maximum treatment duration. Each cycle is 28 days. Dose adjustments
      will be made as appropriate by the investigator.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Response Rate (ORR) (as defined by the IWG Criteria)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Richter's Transformation</condition>
  <arm_group>
    <arm_group_label>selinexor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selinexor</intervention_name>
    <description>60 mg, may be increased to 80 mg after Cycle 1</description>
    <arm_group_label>selinexor</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Richter's transformation, arising in the setting of prior CLL, documented by
             histologically confirmed lymphoma, including large B-cell and immunoblastic variants.

          -  All patients must have received at least one prior regimen for CLL, including
             cytotoxic chemotherapy, anti-CD20 monoclonal antibodies, a BTK inhibitor, or a PI3K
             inhibitor. Patients may have received high dose chemotherapy/autologous stem cell
             transplant (HDT/ASCT) or allogeneic hematopoietic stem cell transplant (allo SCT).

          -  One or more measurable (&gt; 1.5 cm in longest dimension) disease sites on CT
             (preferably PET/CT) or, if CT is contraindicated, MRI (preferably PET/MRI) scans.

          -  Objective documented evidence of disease progression at study entry

          -  ECOG status of ≤ 2

        Exclusion Criteria:

          -  Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks
             prior to Cycle 1 Day 1, except ibrutinib which may be continued until one day prior
             to initiation of selinexor; radio-immunotherapy 4 weeks prior to Cycle 1 Day 1.
             Patients must have recovered to Grade ≤ 1 from clinically significant adverse
             effects.

          -  Prolymphocytic transformation

          -  Less than 1 month since completion of autologous stem cell transplantation or less
             than 3 months since completion of allogeneic stem cell transplantation

          -  Major surgery within 4 weeks of C1D1

          -  Impairment of GI function or GI disease that could interfere with the absorption of
             selinexor, including obstructed GI tract and uncontrolled vomiting or diarrhea.

          -  Inability or unwillingness to take supportive medications including a centrally
             acting appetite stimulant (e.g., mirtazapine or olanzapine) and a peripherally acting
             appetite stimulant (e.g., low dose glucocorticoids or megesterol acetate).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <email>mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisa Powell</last_name>
      <phone>520-694-9048</phone>
      <email>APowell@uacc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Persky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Siddiqi</last_name>
    </contact>
    <investigator>
      <last_name>Tanya Siddiqi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moores Cancer Center / University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of California-Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herbert Eradat</last_name>
      <phone>310-633-8400</phone>
    </contact>
    <investigator>
      <last_name>Herbert Eradat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Heffner</last_name>
      <phone>404-778-1868</phone>
      <email>winshipcto@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Leonard Heffner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Allen, MD</last_name>
      <phone>877-267-6355</phone>
    </contact>
    <investigator>
      <last_name>John Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John C Byrd</last_name>
      <phone>800-293-5066</phone>
    </contact>
    <investigator>
      <last_name>John C Byrd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Stephens</last_name>
      <phone>877-585-0303</phone>
      <email>clinical.trials@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Stephens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Dept. of Hematology, Oncology and Tumor Immunology Charité Medical School</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinik m.S. Hämatologie Onkologie u. Tumorimmunologie Campus Virchow Klinikum Charité Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Hufelandstrasse</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hämostaseologie, Onkologie und Stammzelltransplantation Medizinische Hochschule Hannover</name>
      <address>
        <city>Hanover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Klinik fur Hamatologie, Onkologie, Immunology, Palliativmedizin, Infecktiologie und Tropenmedizin</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nuernberg Hospital</name>
      <address>
        <city>Nuernberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Medyczne</name>
      <address>
        <city>Kraków</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurczak Wojciech</last_name>
      <phone>(012) 295-41-00</phone>
    </contact>
    <investigator>
      <last_name>Wojciech Jurczak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Copernicus Memorial Hospital, Department of Hematology</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tadeusz Robak</last_name>
      <phone>+48 426895010</phone>
    </contact>
    <investigator>
      <last_name>Tadeusz Robak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Skłodowska-Curie Institue of Oncology</name>
      <address>
        <city>Warszawa</city>
        <zip>02-034</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Walewski</last_name>
      <phone>22 546 20 00</phone>
    </contact>
    <investigator>
      <last_name>Jan Walewski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Av.</name>
      <address>
        <city>Barcelona</city>
        <zip>08010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Barcelona-Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Unviersitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Navarra, Pamplona</name>
      <address>
        <city>Navarra</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital: Cancer and Haematology Centre</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 8JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 4, 2016</lastchanged_date>
  <firstreceived_date>May 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Richter's Transformation</keyword>
  <keyword>Richter's Syndrome</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>selinexor</keyword>
  <keyword>KPT-330</keyword>
  <keyword>SIRRT</keyword>
  <keyword>CLL</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
